Fasa Registry on Diabetes Mellitus (FaRD): Feasibility Study and Pilot Phase Results
DOI:
https://doi.org/10.31661/gmj.v10i.2137Keywords:
Diabetes Mellitus; Registry System; Feasibility Study; FasaAbstract
Background: Diabetes mellitus (DM) is the most common chronic disease. This disease is the main risk factor for fatal diseases such as myocardial infarction and stroke. As there is no cure for DM, an effective strategy must control it. Every attempt to control DM and patients’ outcomes require a surveillance system to consider the efficacy and safety measures. Fasa Registry on Diabetes mellitus (FaRD) is the first population-based registry for DM in Iran, which aims to provide an accurate description of social, mental health, clinical, and laboratory values of patients in order to consider the management patterns of these patients and discover the degree of adherence to the recommendations. Materials and Methods: The level of plasma glucose characterizes the diagnosis of diabetes (Type I and II). The pregnant women were excluded from this study. Three registrar nurses collected data from demographics, physical exams, past medical history, medication history, and laboratory findings. Results: The pilot phase included the first 381 patients, of which 257 (67.5%) were women, and 124 (32.5%) were men with a mean age of 57.54 ± 12.12 years among subjects, the 347 (94.5%) cases had DM type 2, and 20 (5.4%) ones had type 1. Conclusion: Based on our results, the characteristics of patients suffering from DM indicated that the jobless ones could not afford their medical expenditures; therefore, the majority of the patients were not adherent to the practice guidelines. The achievement of FaRD helps physicians and patients in improved management of the DM. The findings of this pilot study show the FaRD is feasible, and it will make a comprehensive population-based registry for DM in the region. [GMJ.2021;10:e2137]
References
Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine. McGraw Hill; 2001. Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes Res Clin Pract. 2014;103(2):319-27. https://doi.org/10.1016/j.diabres.2013.12.034PMid:24447808 Rashedi V, Asadi-Lari M, Delbari A, Fadayevatan R, Borhaninejad V, Foroughan M. Prevalence of diabetes type 2 in older adults: Findings from a large population-based survey in Tehran, Iran (Urban HEART-2). Diabetes Metab Syndr. 2017;11:S347-50. https://doi.org/10.1016/j.dsx.2017.03.014PMid:28314537 Akbarzadeh A, Salehi A, Vardanjani HM, Poustchi H, Gandomkar A, Fattahi MR, et al. Epidemiology of adult diabetes mellitus and its correlates in pars cohort study in Southern Iran. Arch Iran Med. 2019;22(11):633-9. Djalalinia S, Modirian M, Sheidaei A, Yoosefi M, Zokaiee H, Damirchilu B, et al. Protocol design for large-scale cross-sectional studies of surveillance of risk factors of non-communicable diseases in Iran: STEPs 2016. Arch Iran Med. 2017;20(9). Witek PW, Wołkow P, Stancel-Możwiłło J, Wojtyczek K, Sieradzki J, Małecki M. The Polish Diabetes Registry for adults-a pilot study. Clinical Diabetology. 2012;1(1):3-11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N engl j med. 1993;329(14):977-86. https://doi.org/10.1056/NEJM199309303291401PMid:8366922 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet. 1998;352(9131):837-53. https://doi.org/10.1016/S0140-6736(98)07019-6 Diabetes Control and Complications Trial. Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N engl j med. 2005;353(25):2643-53. https://doi.org/10.1056/NEJMoa052187PMid:16371630 PMCid:PMC2637991 American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes-2019. Diabetes care. 2019 Jan 1;42(Supplement 1):S34-45. https://doi.org/10.2337/dc19-S004PMid:30559230 American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes care. 2020 Jan 1;43(Supplement 1):S66-76. https://doi.org/10.2337/dc20-S006PMid:31862749 Bahramali E, Askari A, Zakeri H, Farjam M, Dehghan A, Zendehdel K. Fasa Registry on Acute Myocardial Infarction (FaRMI): feasibility study and pilot phase results. PloS one. 2016;11(12):e0167579. https://doi.org/10.1371/journal.pone.0167579PMid:27907128 PMCid:PMC5132161 Bahramali E. Fasa Registry for Systolic Heart Failure (Farsh), Feasibility Study. ActaHealthMedica. 2017;2(2):191-. https://doi.org/10.19082/ah191 Huang Y, Vemer P, Zhu J, Postma MJ, Chen W. Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data. PLoS One. 2016;11(8):e0159297. https://doi.org/10.1371/journal.pone.0159297PMid:27570976 PMCid:PMC5003380 Jiao FF, Fung CS, Wan EY, Chan AK, McGhee SM, Kwok RL, et al. Five-year cost-effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM). Diabetes Care. 2018;41(2):250-7. https://doi.org/10.2337/dc17-1149PMid:29246949 Davari M, Boroumand Z, Amini M, Aslani A, Hosseini M. The direct medical costs of outpatient cares of type 2 diabetes in Iran: A retrospective study. Int J Prev Med. 2016;7. https://doi.org/10.4103/2008-7802.181758PMid:27217937 PMCid:PMC4872475
